JP2011004758A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011004758A5 JP2011004758A5 JP2010183075A JP2010183075A JP2011004758A5 JP 2011004758 A5 JP2011004758 A5 JP 2011004758A5 JP 2010183075 A JP2010183075 A JP 2010183075A JP 2010183075 A JP2010183075 A JP 2010183075A JP 2011004758 A5 JP2011004758 A5 JP 2011004758A5
- Authority
- JP
- Japan
- Prior art keywords
- antibodies
- column
- chimeric
- mutations
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000035772 mutation Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 1
Description
表1：実施例で用いられるキメラ及びヒト化抗CD37抗体の可変重鎖及び軽鎖の配列
表2：キメラ及びヒト化抗CD37抗体の可変重鎖及び軽鎖配列（列III及びIV）並びに変異（列II）（抗体A0、B0、C0などは、表1の抗体A、B、Cなどと同一である）
重鎖及び軽鎖の完全長配列は列VおよびVIに記載される（星印を付した列Vの配列は、列IIに対応する置換（及びコードDNAに対応する変異）を含むように改変した配列番号:24及び23（野生型）のIgG1配列に該当する）
重鎖及び軽鎖の完全長配列は列VおよびVIに記載される（星印を付した列Vの配列は、列IIに対応する置換（及びコードDNAに対応する変異）を含むように改変した配列番号:24及び23（野生型）のIgG1配列に該当する）
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07114128.7 | 2007-08-09 | ||
| EP07114128 | 2007-08-09 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010519473A Division JP5325216B2 (ja) | 2007-08-09 | 2008-08-08 | 抗ｃｄ３７抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011004758A JP2011004758A (ja) | 2011-01-13 |
| JP2011004758A5 true JP2011004758A5 (ja) | 2011-10-06 |
| JP5238000B2 JP5238000B2 (ja) | 2013-07-17 |
Family
ID=38925567
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010519473A Active JP5325216B2 (ja) | 2007-08-09 | 2008-08-08 | 抗ｃｄ３７抗体 |
| JP2010183075A Active JP5238000B2 (ja) | 2007-08-09 | 2010-08-18 | 抗ｃｄ３７抗体 |
| JP2013150731A Withdrawn JP2014039541A (ja) | 2007-08-09 | 2013-07-19 | 抗ｃｄ３７抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010519473A Active JP5325216B2 (ja) | 2007-08-09 | 2008-08-08 | 抗ｃｄ３７抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013150731A Withdrawn JP2014039541A (ja) | 2007-08-09 | 2013-07-19 | 抗ｃｄ３７抗体 |
Country Status (37)
| Country | Link |
|---|---|
| US (7) | US20100189722A1 (ja) |
| EP (3) | EP2178915B1 (ja) |
| JP (3) | JP5325216B2 (ja) |
| KR (1) | KR101593403B1 (ja) |
| CN (4) | CN102276724A (ja) |
| AR (2) | AR071242A1 (ja) |
| AU (1) | AU2008285590B2 (ja) |
| BR (2) | BRPI0815369A2 (ja) |
| CA (1) | CA2693464C (ja) |
| CL (3) | CL2008002349A1 (ja) |
| CO (1) | CO6251371A2 (ja) |
| CY (1) | CY1117101T1 (ja) |
| DK (1) | DK2178915T3 (ja) |
| EA (2) | EA027499B1 (ja) |
| EC (2) | ECSP109946A (ja) |
| ES (1) | ES2555202T3 (ja) |
| HK (1) | HK1220708A1 (ja) |
| HR (1) | HRP20160009T1 (ja) |
| HU (1) | HUE026221T2 (ja) |
| IL (1) | IL202645A (ja) |
| MA (1) | MA32665B1 (ja) |
| ME (1) | ME02300B (ja) |
| MY (1) | MY157555A (ja) |
| NZ (2) | NZ600022A (ja) |
| PE (3) | PE20120259A1 (ja) |
| PH (1) | PH12014501812B1 (ja) |
| PL (1) | PL2178915T3 (ja) |
| PT (1) | PT2178915E (ja) |
| RS (1) | RS54359B1 (ja) |
| SG (1) | SG190657A1 (ja) |
| SI (1) | SI2178915T1 (ja) |
| TN (1) | TN2010000068A1 (ja) |
| TW (2) | TW201512220A (ja) |
| UA (2) | UA105445C2 (ja) |
| UY (1) | UY31275A1 (ja) |
| WO (1) | WO2009019312A2 (ja) |
| ZA (1) | ZA200908758B (ja) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2007014278A2 (en) | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals, Inc. | B-cell reduction using cd37-specific and cd20-specific binding molecules |
| EP2418223A3 (en) | 2006-06-12 | 2013-01-16 | Emergent Product Development Seattle, LLC | Single-chain multivalent binding proteins with effector function |
| PE20120259A1 (es) * | 2007-08-09 | 2012-04-04 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| CA2700673A1 (en) * | 2007-09-24 | 2009-04-02 | Tragara Pharmaceuticals, Inc. | Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors |
| BRPI0911377A8 (pt) | 2008-04-11 | 2017-12-05 | Trubion Pharmaceuticals Inc | Imunoterápico de cd7 e combinação com quimioterápico bifuncional deste |
| SI2516468T1 (sl) * | 2009-12-23 | 2016-06-30 | Synimmune Gmbh | Protitelesa proti flt3 in postopki uporabe istih |
| NO331080B1 (no) * | 2010-01-29 | 2011-09-26 | Nordic Nanovector As | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
| AU2011226672B2 (en) * | 2010-03-12 | 2015-07-23 | Immunogen, Inc. | CD37-binding molecules and immunoconjugates thereof |
| US20120189618A1 (en) * | 2010-07-16 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Superior efficacy of cd37 antibodies in cll blood samples |
| UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| US20120107317A1 (en) * | 2010-10-27 | 2012-05-03 | The University Of Hong Kong | Use of cytoplasmic c-myc for regulating immune responses |
| SG193447A1 (en) * | 2011-04-01 | 2013-10-30 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
| EP2710042A2 (en) | 2011-05-16 | 2014-03-26 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| BR112014014258A2 (pt) * | 2011-12-13 | 2020-10-27 | Nordic Nanovector As. | molécula de anticorpo que se liga a cd37 humano; anticorpo; molécula de dna; vetor de expressão; célula hospedeira; método para produzir um anticorpo; composição farmacêutica; método de esgotamento de células b que expressam cd37 dentre uma população de células; radioimunoconjugado que se liga a cd37 humano; método de tratamento de uma malignidade de célula b; kit para a produção do radioimunoconjugado; e preparação injetável de anticorpo hh1 quimérico ou humanizado para uso no pré-tratamento de uma malignidade de célula b |
| KR20140143810A (ko) * | 2012-03-30 | 2014-12-17 | 이뮤노젠 아이엔씨 | Cd37 기반 치료의 효과를 증대시키는 방법 |
| US20130287797A1 (en) * | 2012-04-26 | 2013-10-31 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with bendamustine |
| JP2015517511A (ja) * | 2012-05-16 | 2015-06-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用 |
| EP2849783A1 (en) | 2012-05-16 | 2015-03-25 | Boehringer Ingelheim International GmbH | Combination of cd37 antibodies with further agents |
| EP2852388A4 (en) * | 2012-05-23 | 2016-01-13 | Univ Johns Hopkins | COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| WO2014151438A1 (en) * | 2013-03-15 | 2014-09-25 | Emergent Product Development Seattle, Llc | Multispecific anti-cd37 antibodies and related compositions and methods |
| US20160106837A1 (en) * | 2013-06-14 | 2016-04-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with chlorambucil |
| CN105722534B (zh) | 2013-08-01 | 2019-05-31 | 艾更斯司股份有限公司 | 结合cd37蛋白的抗体药物偶联物(adc) |
| US9291244B2 (en) | 2014-01-17 | 2016-03-22 | Ford Global Technologies, Llc | Nine speed automatic transmission |
| EP2966085A1 (en) | 2014-07-11 | 2016-01-13 | Boehringer Ingelheim International GmbH | Antibody IgG1 with a modified heavy chain constant region |
| CN107849144B (zh) | 2015-05-29 | 2021-09-17 | 艾吉纳斯公司 | 抗-ctla-4抗体及其使用方法 |
| BR112017026027A2 (pt) | 2015-06-08 | 2018-08-14 | Debiopharm Int Sa | combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20 |
| TR201816369T4 (tr) * | 2015-07-28 | 2018-11-21 | Forschungszentrum Borstel Leibniz Lungenzentrum | Endotoksin tayinine yönelik iyileştirilmiş bakteriyel endotoksin testi. |
| CN108699144B (zh) | 2015-08-28 | 2022-07-19 | 德彪发姆国际有限公司 | 用于检测cd37的抗体和测定 |
| US11352426B2 (en) | 2015-09-21 | 2022-06-07 | Aptevo Research And Development Llc | CD3 binding polypeptides |
| CA3017776A1 (en) | 2016-03-15 | 2017-09-21 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
| US11278629B2 (en) | 2016-11-02 | 2022-03-22 | Debiopharm International, S.A. | Methods for improving anti-CD37 immunoconjugate therapy |
| IL307242A (en) | 2016-12-07 | 2023-11-01 | Agenus Inc | Anti-CTLA-4 antibodies and methods of using them |
| WO2018132506A1 (en) | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
| EP3595721B1 (en) | 2017-03-16 | 2025-07-09 | The General Hospital Corporation | Chimeric antigen receptors targeting cd37 |
| KR102706161B1 (ko) | 2017-03-31 | 2024-09-19 | 젠맵 홀딩 비.브이. | 이중특이적 항-cd37 항체, 모노클로날 항-cd37 항체 및 그의 사용 방법 |
| ES2996886T3 (en) * | 2017-06-27 | 2025-02-13 | Regeneron Pharma | Rodents comprising a humanized asgr1 locus |
| JP2021525735A (ja) | 2018-05-30 | 2021-09-27 | デビオファーム インターナショナル， エス． アー． | 抗ｃｄ３７免疫コンジュゲート投薬レジメン |
| US12275797B2 (en) | 2018-06-22 | 2025-04-15 | Genmab Holding B.V. | Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof |
| EP3793578A4 (en) * | 2018-06-22 | 2022-03-23 | The General Hospital Corporation | Chimeric antigen receptors targeting cd37 and cd19 |
| WO2020004337A1 (ja) * | 2018-06-27 | 2020-01-02 | 国立大学法人名古屋大学 | Ｃｄ３７特異的キメラ抗原レセプター |
| EP3847196A4 (en) | 2018-09-07 | 2023-01-04 | ITabMed (HK) Limited | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
| BR112021006055A2 (pt) | 2018-10-04 | 2021-07-20 | Genmab Holding B.V. | composição farmacêutica, uso da composição farmacêutica, e, métodos para induzir a morte celular ou para inibir o crescimento e/ou proliferação de uma célula tumoral e para tratar um indivíduo. |
| JP2022545834A (ja) * | 2019-08-30 | 2022-10-31 | クイル ピュージェット サウンド バイオセラピューティクス コーポレーション | 抗ｃｄ２０抗体、抗ｃｄ３７抗体、およびこれらの混合物 |
| EP4405398A4 (en) * | 2021-09-21 | 2025-10-29 | Qilu Puget Sound Biotherapeutics Corp | FC HETERODIMERS ALLOWING THE MANUFACTURE OF FUSION PROTEINS AND BI-SPECIFIC ANTIBODIES |
| WO2023057583A1 (en) | 2021-10-06 | 2023-04-13 | Nordic Nanovector Asa | Humanized hh1 |
| WO2023057595A1 (en) | 2021-10-06 | 2023-04-13 | Nordic Nanovector Asa | Humanized hh1 rew |
| AU2022368385A1 (en) | 2021-10-18 | 2024-04-11 | Daiichi Sankyo Company, Limited | Anti-cd37 antibody-drug conjugate |
| WO2024118480A1 (en) * | 2022-11-28 | 2024-06-06 | Epiphany Biosciences | Use of antiviral agents, composition of matter, combination preparations/agents to treat chronic diseases associated with epstein-barr virus and other human herpes viruses |
| WO2025083205A1 (en) | 2023-10-18 | 2025-04-24 | Debiopharm International S.A. | Drug combination comprising anti-cd37 antibody maytansine conjugate and bcl2 inhibitor or pi3k inhibitor |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| EP0247091B1 (en) | 1985-11-01 | 1993-09-29 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| GB8800077D0 (en) * | 1988-01-05 | 1988-02-10 | Ciba Geigy Ag | Novel chimeric antibodies |
| EP0417193B1 (en) | 1988-05-27 | 1993-08-04 | Centocor, Inc. | Freeze-dried formulation for antibody products |
| ATE190355T1 (de) * | 1988-09-06 | 2000-03-15 | Xoma Corp | Genexpressions-elemente und herstellung von chimären maus-mensch-antikörpern |
| ATE289350T1 (de) | 1989-04-21 | 2005-03-15 | Amgen Inc | Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| EP0602126B1 (en) | 1991-08-14 | 2003-03-05 | Genentech, Inc. | Immunoglobulin variants for specific fc epsilon receptors |
| ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DE69420137T2 (de) | 1993-06-03 | 1999-12-23 | Therapeutic Antibodies, Inc. | Herstellung von antikörperfragmenten |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| EP0904107B1 (en) | 1996-03-18 | 2004-10-20 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| WO1998005787A1 (en) | 1996-08-02 | 1998-02-12 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
| AU758240B2 (en) | 1998-02-25 | 2003-03-20 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
| DE19911329A1 (de) | 1998-03-27 | 2000-09-21 | Benes Ivan Friedrich | Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung |
| ES2532910T3 (es) | 1998-04-02 | 2015-04-01 | Genentech, Inc. | Variantes de anticuerpos y fragmentos de los mismos |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| JP2003514903A (ja) | 1999-11-24 | 2003-04-22 | イムノージェン インコーポレーテッド | タキサンを含有する細胞傷害薬とその治療への利用 |
| WO2001049698A1 (en) | 1999-12-29 | 2001-07-12 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2004016753A2 (en) | 2002-08-15 | 2004-02-26 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| EP1519959B1 (en) * | 2002-02-14 | 2014-04-02 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
| PT1534335E (pt) | 2002-08-14 | 2012-02-28 | Macrogenics Inc | Anticorpos específicos de fcγriib e processos para a sua utilização |
| EP3321282A1 (en) | 2002-09-27 | 2018-05-16 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| JP4768439B2 (ja) | 2002-10-15 | 2011-09-07 | アボット バイオセラピューティクス コーポレイション | 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変 |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| KR101441358B1 (ko) | 2003-05-14 | 2014-09-24 | 이뮤노젠 아이엔씨 | 약물 콘쥬게이트 조성물 |
| US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| US20050249723A1 (en) | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
| EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| SI2471813T1 (sl) | 2004-07-15 | 2015-03-31 | Xencor, Inc. | Optimirane Fc variante |
| US20060074225A1 (en) | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| AU2005304624B2 (en) | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US20080279850A1 (en) | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
| WO2007014278A2 (en) | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals, Inc. | B-cell reduction using cd37-specific and cd20-specific binding molecules |
| WO2007041635A2 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| CN103554259B (zh) | 2005-10-12 | 2016-05-18 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| BRPI0814060A2 (pt) | 2007-07-06 | 2015-01-06 | Trubion Pharmaceuticals Inc | Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal |
| PE20120259A1 (es) * | 2007-08-09 | 2012-04-04 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| BRPI0911377A8 (pt) | 2008-04-11 | 2017-12-05 | Trubion Pharmaceuticals Inc | Imunoterápico de cd7 e combinação com quimioterápico bifuncional deste |
| CA2731255C (en) | 2008-07-21 | 2018-06-05 | David M. Goldenberg | Structural variants of antibodies for improved therapeutic characteristics |
| US20100135900A1 (en) | 2008-11-13 | 2010-06-03 | Trubion Pharmaceuticals, Inc. | Cd37 immunotherapeutic combination therapies and uses thereof |
| US20120189618A1 (en) * | 2010-07-16 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Superior efficacy of cd37 antibodies in cll blood samples |
| US20130287797A1 (en) * | 2012-04-26 | 2013-10-31 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with bendamustine |
| JP2015517511A (ja) * | 2012-05-16 | 2015-06-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用 |
| EP2849783A1 (en) * | 2012-05-16 | 2015-03-25 | Boehringer Ingelheim International GmbH | Combination of cd37 antibodies with further agents |
| US20160106837A1 (en) | 2013-06-14 | 2016-04-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with chlorambucil |
-
2008
- 2008-08-07 PE PE2011000972A patent/PE20120259A1/es active IP Right Grant
- 2008-08-07 PE PE2008001321A patent/PE20090499A1/es active IP Right Grant
- 2008-08-07 PE PE2013000843A patent/PE20140196A1/es not_active Application Discontinuation
- 2008-08-08 MY MYPI2010000565A patent/MY157555A/en unknown
- 2008-08-08 JP JP2010519473A patent/JP5325216B2/ja active Active
- 2008-08-08 EP EP08787055.6A patent/EP2178915B1/en active Active
- 2008-08-08 CN CN2011102205939A patent/CN102276724A/zh active Pending
- 2008-08-08 BR BRPI0815369-8A patent/BRPI0815369A2/pt active Search and Examination
- 2008-08-08 ME MEP-2015-191A patent/ME02300B/me unknown
- 2008-08-08 SG SG2013037619A patent/SG190657A1/en unknown
- 2008-08-08 PL PL08787055T patent/PL2178915T3/pl unknown
- 2008-08-08 CN CN201510756148.2A patent/CN105273086A/zh active Pending
- 2008-08-08 BR BRPI0823331-4A2A patent/BRPI0823331A2/pt not_active Application Discontinuation
- 2008-08-08 KR KR1020107002636A patent/KR101593403B1/ko not_active Expired - Fee Related
- 2008-08-08 CN CN200880102642A patent/CN101815725A/zh active Pending
- 2008-08-08 NZ NZ600022A patent/NZ600022A/xx not_active IP Right Cessation
- 2008-08-08 EP EP10168244A patent/EP2241577A1/en not_active Withdrawn
- 2008-08-08 EA EA201000274A patent/EA027499B1/ru not_active IP Right Cessation
- 2008-08-08 DK DK08787055.6T patent/DK2178915T3/en active
- 2008-08-08 CN CN2013102616193A patent/CN103396490A/zh active Pending
- 2008-08-08 EP EP12185691.8A patent/EP2562187B1/en active Active
- 2008-08-08 TW TW103121994A patent/TW201512220A/zh unknown
- 2008-08-08 UA UAA201303569A patent/UA105445C2/uk unknown
- 2008-08-08 CA CA2693464A patent/CA2693464C/en not_active Expired - Fee Related
- 2008-08-08 UY UY31275A patent/UY31275A1/es not_active Application Discontinuation
- 2008-08-08 NZ NZ583713A patent/NZ583713A/en not_active IP Right Cessation
- 2008-08-08 PT PT87870556T patent/PT2178915E/pt unknown
- 2008-08-08 ES ES08787055.6T patent/ES2555202T3/es active Active
- 2008-08-08 HR HRP20160009TT patent/HRP20160009T1/hr unknown
- 2008-08-08 AR ARP080103490A patent/AR071242A1/es not_active Application Discontinuation
- 2008-08-08 SI SI200831544T patent/SI2178915T1/sl unknown
- 2008-08-08 TW TW097130378A patent/TWI535733B/zh not_active IP Right Cessation
- 2008-08-08 HU HUE08787055A patent/HUE026221T2/en unknown
- 2008-08-08 WO PCT/EP2008/060464 patent/WO2009019312A2/en not_active Ceased
- 2008-08-08 EA EA201200994A patent/EA201200994A1/ru unknown
- 2008-08-08 UA UAA201002500A patent/UA103005C2/ru unknown
- 2008-08-08 US US12/672,378 patent/US20100189722A1/en not_active Abandoned
- 2008-08-08 CL CL2008002349A patent/CL2008002349A1/es unknown
- 2008-08-08 AU AU2008285590A patent/AU2008285590B2/en not_active Ceased
- 2008-08-08 RS RS20150817A patent/RS54359B1/sr unknown
-
2009
- 2009-12-09 ZA ZA200908758A patent/ZA200908758B/xx unknown
- 2009-12-10 IL IL202645A patent/IL202645A/en active IP Right Grant
-
2010
- 2010-02-08 TN TNP2010000068A patent/TN2010000068A1/fr unknown
- 2010-02-09 CO CO10014090A patent/CO6251371A2/es not_active Application Discontinuation
- 2010-02-09 MA MA32605A patent/MA32665B1/fr unknown
- 2010-02-09 EC EC2010009946A patent/ECSP109946A/es unknown
- 2010-08-18 JP JP2010183075A patent/JP5238000B2/ja active Active
- 2010-09-17 US US12/884,563 patent/US20110165153A1/en not_active Abandoned
- 2010-12-02 HK HK16108880.8A patent/HK1220708A1/zh unknown
-
2011
- 2011-06-24 CL CL2011001592A patent/CL2011001592A1/es unknown
- 2011-08-03 EC EC2011009946A patent/ECSP11009946A/es unknown
-
2012
- 2012-08-22 CL CL2012002329A patent/CL2012002329A1/es unknown
-
2013
- 2013-07-19 JP JP2013150731A patent/JP2014039541A/ja not_active Withdrawn
- 2013-08-23 US US13/974,230 patent/US20140004110A1/en not_active Abandoned
- 2013-08-23 US US13/974,226 patent/US9078879B2/en active Active
-
2014
- 2014-08-11 PH PH12014501812A patent/PH12014501812B1/en unknown
-
2015
- 2015-04-22 US US14/693,047 patent/US9932399B2/en active Active
-
2016
- 2016-01-12 CY CY20161100025T patent/CY1117101T1/el unknown
-
2017
- 2017-03-16 AR ARP170100658A patent/AR107902A2/es unknown
-
2018
- 2018-02-15 US US15/897,400 patent/US20180186876A1/en not_active Abandoned
-
2020
- 2020-11-04 US US17/088,765 patent/US20210230271A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011004758A5 (ja) | ||
| HRP20211343T1 (hr) | Protutijela protiv dkk-1 | |
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| JP2014012688A5 (ja) | ||
| RU2014108208A (ru) | Мыши с гуманизированной универсальной легкой цепью | |
| JP2019528240A5 (ja) | ||
| NZ715896A (en) | Humanized or chimeric cd3 antibodies | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| RU2017105120A (ru) | Cd3-связывающий домен | |
| ES2721753T3 (es) | Anticuerpos contra IL-6 y usos de los mismos | |
| PE20140196A1 (es) | Anticuerpos anti-cd37 | |
| EP3839049A3 (en) | Antibodies, variable domains & chains tailored for human use | |
| WO2012068540A3 (en) | Neutralizing anti-ccl20 antibodies | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| EP4345163A3 (en) | Genetic engineering of non-human animals for the production of chimeric antibodies | |
| EA201591153A1 (ru) | Антитела, связывающиеся с tl1a, и их применение | |
| WO2013173496A3 (en) | Cd33 antibodies and use of same to treat cancer | |
| EA201990959A1 (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток | |
| EA201291161A3 (ru) | Связывающие csf1r антитела | |
| AR083293A1 (es) | Agentes de union a cd33 | |
| JP2013539361A5 (ja) | ||
| GB2525568A (en) | Single cell bar-coding for antibody discovery | |
| WO2011139974A3 (en) | Anti-pai-1 antibodies and methods of use thereof | |
| EA201492163A1 (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К TrkA, СОДЕРЖАЩИЕ АМИНОКИСЛОТНЫЕ ЗАМЕНЫ | |
| JP2013502204A5 (ja) |